Fundraise

Seawolf exits stealth with $100M for DNA-based therapies

What's the deal? Seawolf Therapeutics, a San Diego biotech, emerged from stealth with $100 million in Series A funding to develop DNA-based medicines. Founding investor Versant Ventures led the round, joined by MPM BioImpactDealroom has a profile for this one. Try Dealroom →, Alexandria Venture InvestmentsDealroom has a profile for this one. Try Dealroom →, Eli Lilly, and CRISPR Therapeutics.

What's the endgame? Seawolf's "TRIDENT" platform uses lipid nanoparticles to deliver engineered DNA into cells, where it instructs them to make disease-fighting proteins. The company says its therapies last longer than RNA-based treatments and, unlike virus-based delivery, can be redosed.

What's the product? The money will advance Seawolf's lead program for metabolic diseases. The company also disclosed a multi-target research collaboration and license deal with Sanofi targeting bleeding disorders, worth up to $1.2 billion in milestone payments plus tiered royalties.

What could go wrong? Seawolf says its medicines proved potent, durable, and safe in primate tests. The key test ahead is showing the platform can safely reach target tissues and produce durable effects in people.

Why now? The round lands amid renewed investor interest in genetic medicines that solve delivery and durability problems, not just new payloads. In June, SonoThera raised $125 million for its own nonviral genetic therapies.

The signal: Venture money for metabolic disease drugmakers has cooled, falling to about $740 million this year from nearly $1.3 billion in 2025, per BioPharma Dive. Seawolf's $100 million round is a substantial bet that durable, redosable DNA medicines can buck that trend.

Read more: finance.yahoo.com

Image credit: Generated with Gemini

More top stories